Poseida Therapeutics Inc

NASDAQ:PSTXUnited States

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Its approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle and hybrid gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Its lead programs, including P-FVIII-101, a non-viral approach. Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. P-BCMA-ALLO1 is in a Phase I trial, being developed for patients with relapsed/refractory multiple myeloma.

Contact Information

Headquarters

9390 TOWNE CENTRE DRIVE, SUITE 200SAN DIEGO, CA, United States 92121

Phone

858-779-3100

Fax

302-636-5454

Executives

Executive Chairman of the Board

Mark Gergen

President - Cell Therapy

Kristin Yarema

Chief Financial Officer

Johanna Mylet

Chief Operations Officer

Loren Wagner

General Counsel, Chief Compliance Officer and Corporate Secretary

Harry Leonhardt